Analyzing HDL Lipoproteins in Patients with Depression

DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls

This study is testing how certain fats in the blood might connect depression with heart problems in people who have moderate to severe depression compared to healthy individuals.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 90 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Centre Hospitalier Universitaire Dijon (other)
• Locations: 1 site (Dijon)
• Trial ID: NCT05099341 on ClinicalTrials.gov

What this trial studies

This study investigates the relationship between depression and cardiovascular disease by analyzing the functional and lipidomic properties of HDL lipoproteins in patients with moderate to severe depression compared to healthy controls. It aims to understand how lipid abnormalities may contribute to the increased cardiovascular risk observed in individuals suffering from depression. Participants will undergo assessments using the HDRS-17 depression scale and provide blood samples for analysis. The findings could shed light on potential mechanisms linking depression to cardiovascular issues.

Who should consider this trial

Good fit: Ideal candidates include adults with moderate to severe depression, either recurrent or experiencing their first depressive episode, as well as healthy controls without a history of depression.

Not a fit: Patients with metabolic syndrome or those unable to provide consent may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in patients with depression.

How similar studies have performed: While the specific approach of analyzing HDL lipoproteins in this context may be novel, previous studies have indicated a link between lipid abnormalities and cardiovascular risks in depressed populations.

Eligibility criteria

Inclusion Criteria:

* FOR PATIENTS WITH RECURRENT DEPRESSION :

  * Patient who has provided oral consent
  * Adult with moderate to severe depression according to DSM-5 criteria (Hamilton HDRS-17 score ≥ 18), with a number of depressive episodes ≥ 3
* PATIENTS PRESENTING WITH A FIRST DEPRESSIVE EPISODE

  * Patient who has provided oral consent
  * Adult with moderate to severe characterized depression according to DSM-5 criteria (Hamilton HDRS-17 scale score ≥ 18) presenting with a first depressive episode.
* CONTROLS

  * Person who has provided oral consent
  * Adult who has never shown signs of depression

Exclusion Criteria:

* Person not affiliated with national health insurance
* Person subject to a measure of legal protection (curatorship, guardianship)
* Pregnant or breastfeeding women
* Adult unable to express consent
* Minors
* Person with a metabolic syndrome (according to NCEP/ATP-III criteria: 3 of the following 5 criteria: Waist circumference ≥ 102 cm in males and ≥ 88cm in females, Triglycerides \> 1.50 g/L, HDL-Cholesterol \< 0.40 g/L in H, HDL-Cholesterol \< 0.50 g/L in F, Blood pressure ≥130/85mmHg, Fasting blood glucose ≥ 1.10 g/L),
* Person with type 1 or type 2 diabetes,
* Person with a mild depressive episode (HDRS-17\<18),
* Person with concomitant antipsychotic treatment
* Person with bipolar disorder,
* Person with a moderate to severe alcohol use disorder according to DSM-5 criteria
* Person with schizophrenia,
* Person with a persistent delusional disorder,
* Person with an autism spectrum disorder.

Where this trial is running

Dijon

• Chu Dijon Bourgogne — Dijon, France (RECRUITING)

Study contacts

• Study coordinator: Jean-Christophe CHAUVET-GELINIER

Conditions: Depression